Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials.

Aim

To elucidate the associations of pre-biologic individual biomarker levels or their combinations with pre-to-post biologic changes in asthma outcomes in real-life.

Methods

This was a registry-based, cohort study using data from 23 countries, which shared data with the International Severe Asthma Registry (May 2017-February 2023). The investigated biomarkers (highest pre-biologic levels) were immunoglobulin E (IgE), blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO). Pre- to approximately 12-month post-biologic change for each of three asthma outcome domains (i.e. exacerbation rate, symptom control and lung function), and the association of this change with pre-biologic biomarkers was investigated for individual and combined biomarkers.

Results

Overall, 3751 patients initiated biologics and were included in the analysis. No association was found between pre-biologic BEC and pre-to-post biologic change in exacerbation rate for any biologic class. However, higher pre-biologic BEC and FeNO were both associated with greater post-biologic improvement in FEV ₁ for both anti-IgE and anti-IL5/5R, with a trend for anti-IL4Rα. Mean FEV ₁ improved by 27-178 mL post-anti-IgE as pre-biologic BEC increased (250 to 1000 cells/µL), and by 43-216 mL and 129-250 mL post-anti-IL5/5R and -anti-IL4Rα, respectively along the same BEC gradient. Corresponding improvements along a FeNO gradient (25-100 ppb) were 41-274 mL, 69-207 mL and 148-224 mL for anti-IgE, anti-IL5/5R, and anti-IL4Rα, respectively. Higher baseline BEC was also associated with lower probability of uncontrolled asthma (OR 0.392; p=0.001) post-biologic for anti-IL5/5R. Pre-biologic IgE was a poor predictor of subsequent pre-to-post-biologic change for all outcomes assessed for all biologics. The combination of BEC + FeNO marginally improved the prediction of post-biologic FEV ₁ increase (adjusted R ²: 0.751), compared to BEC (adjusted R ²: 0.747) or FeNO alone (adjusted R ²: 0.743) (p=0.005 and <0.001, respectively); however, this prediction was not improved by the addition of IgE.

Conclusions

The ability of higher baseline BEC, FeNO and their combination to predict biologic-associated lung function improvement may encourage earlier intervention in patients with impaired lung function or at risk of accelerated lung function decline.

Related collections

Most cited references 55

Record: found
Abstract: found
Article: not found

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. FitzGerald, Eugene R. Bleecker, Parameswaran Nair … (2016)

Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.

0 comments Cited 521 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Development and validation of a questionnaire to measure asthma control

E.F. Juniper, P.M. O′byrne, G.h Guyatt … (2000)

International guidelines on asthma management indicate that the primary goal of treatment should be optimum asthma control. The aim of this study was to develop and validate the Asthma Control Questionnaire (ACQ). The authors generated a list of all symptoms used to assess control and sent it to 100 asthma clinicians who were members of guidelines committees (18 countries). They scored each symptom for its importance in evaluating asthma control. From the 91 responses, the five highest scoring symptoms were selected for the ACQ. In addition, there is one question on beta2-agonist use and another on airway calibre (total questions=7). The ACQ was tested in a 9-week observational study of 50 adults with symptomatic asthma. The ACQ and other measures of asthma health status were assessed at baseline, 1, 5 and 9 weeks. In patients whose asthma was stable between clinic visits, reliability of the ACQ was high (intraclass correlation coefficient (ICC)=0.90). The questionnaire was very responsive to change in asthma control (p<0.0001). Cross-sectional and longitudinal validity were supported by correlations between the ACQ and other measures of asthma health status being close to a priori predictions. In conclusion, the Asthma Control Questionnaire has strong evaluative and discriminative properties and can be used with confidence to measure asthma control.

0 comments Cited 462 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Development of the asthma control test: a survey for assessing asthma control.

Robert A Nathan, Christine A Sorkness, Mark Kosinski … (2004)

Asthma guidelines indicate that the goal of treatment should be optimum asthma control. In a busy clinic practice with limited time and resources, there is need for a simple method for assessing asthma control with or without lung function testing. The objective of this article was to describe the development of the Asthma Control Test (ACT), a patient-based tool for identifying patients with poorly controlled asthma. A 22-item survey was administered to 471 patients with asthma in the offices of asthma specialists. The specialist's rating of asthma control after spirometry was also collected. Stepwise regression methods were used to select a subset of items that showed the greatest discriminant validity in relation to the specialist's rating of asthma control. Internal consistency reliability was computed, and discriminant validity tests were conducted for ACT scale scores. The performance of ACT was investigated by using logistic regression methods and receiver operating characteristic analyses. Five items were selected from regression analyses. The internal consistency reliability of the 5-item ACT scale was 0.84. ACT scale scores discriminated between groups of patients differing in the specialist's rating of asthma control (F = 34.5, P <.00001), the need for change in patient's therapy (F = 40.3, P <.00001), and percent predicted FEV(1) (F = 4.3, P =.0052). As a screening tool, the overall agreement between ACT and the specialist's rating ranged from 71% to 78% depending on the cut points used, and the area under the receiver operating characteristic curve was 0.77. Results reinforce the usefulness of a brief, easy to administer, patient-based index of asthma control.

0 comments Cited 442 times – based on 0 reviews      Review now

All references

Author and article information

Contributors

Celeste M. Porsbjerg: Role: Role:

John Townend: URI : https://loop.frontiersin.org/people/2625567Role: Role:

Celine Bergeron: Role: Role:

George C. Christoff: URI : https://loop.frontiersin.org/people/671402Role: Role:

Gregory P. Katsoulotos: Role: Role:

Désirée Larenas-Linnemann: Role: Role:

Trung N. Tran: Role: Role:

Riyad Al-Lehebi: Role: Role:

Sinthia Z. Bosnic-Anticevich: URI : https://loop.frontiersin.org/people/978258Role: Role:

John Busby: Role: Role:

Mark Hew: Role: Role:

Konstantinos Kostikas: URI : https://loop.frontiersin.org/people/190690Role: Role:

Nikolaos G. Papadopoulos: URI : https://loop.frontiersin.org/people/450029Role: Role:

Paul E. Pfeffer: URI : https://loop.frontiersin.org/people/1006674Role: Role:

Todor A. Popov: URI : https://loop.frontiersin.org/people/1318636Role: Role:

Chin Kook Rhee: URI : https://loop.frontiersin.org/people/1280768Role: Role:

Mohsen Sadatsafavi: Role: Role:

Ming-Ju Tsai: URI : https://loop.frontiersin.org/people/837853Role: Role:

Charlotte Suppli Ulrik: Role: Role:

Mona Al-Ahmad: URI : https://loop.frontiersin.org/people/901899Role: Role:

Alan Altraja: Role: Role:

Aaron Beastall: Role: Role:

Lakmini Bulathsinhala: Role: Role:

Victoria Carter: Role: Role:

Borja G. Cosio: URI : https://loop.frontiersin.org/people/2304072Role: Role:

Kirsty Fletton: Role: Role:

Susanne Hansen: Role: Role:

Liam G. Heaney: URI : https://loop.frontiersin.org/people/820452Role: Role:

Richard B. Hubbard: Role: Role:

Piotr Kuna: Role: Role:

Ruth B. Murray: URI : https://loop.frontiersin.org/people/2632604Role: Role:

Tatsuya Nagano: URI : https://loop.frontiersin.org/people/2667455Role: Role:

Laura Pini: URI : https://loop.frontiersin.org/people/1299970Role: Role:

Diana Jimena Cano Rosales: URI : https://loop.frontiersin.org/people/2678105Role: Role:

Florence Schleich: Role: Role:

Michael E. Wechsler: URI : https://loop.frontiersin.org/people/1970019Role: Role:

Rita Amaral: Role: Role:

Arnaud Bourdin: Role: Role:

Guy G. Brusselle: Role: Role:

Wenjia Chen: Role: Role:

Li Ping Chung: URI : https://loop.frontiersin.org/people/640246Role: Role:

Eve Denton: Role: Role:

Joao A. Fonseca: URI : https://loop.frontiersin.org/people/851914Role: Role:

Flavia Hoyte: Role: Role:

David J. Jackson: URI : https://loop.frontiersin.org/people/999720Role: Role:

Rohit Katial: Role: Role:

Bruce J. Kirenga: Role: Role:

Mariko Siyue Koh: Role: Role:

Agnieszka Ławkiedraj: URI : https://loop.frontiersin.org/people/2677462Role: Role:

Lauri Lehtimäki: Role: Role:

Mei Fong Liew: Role: Role:

Bassam Mahboub: URI : https://loop.frontiersin.org/people/815440Role: Role:

Neil Martin: Role: Role:

Andrew N. Menzies-Gow: Role: Role:

Pee Hwee Pang: Role: Role:

Andriana I. Papaioannou: URI : https://loop.frontiersin.org/people/990211Role: Role:

Pujan H. Patel: URI : https://loop.frontiersin.org/people/2221450Role: Role:

Luis Perez-De-Llano: Role: Role:

Matthew J. Peters: Role: Role:

Luisa Ricciardi: URI : https://loop.frontiersin.org/people/1528649Role: Role:

Bellanid Rodríguez-Cáceres: URI : https://loop.frontiersin.org/people/2677634Role: Role:

Ivan Solarte: Role: Role:

Tunn Ren Tay: Role: Role:

Carlos A. Torres-Duque: URI : https://loop.frontiersin.org/people/1323074Role: Role:

Eileen Wang: Role: Role:

Martina Zappa: URI : https://loop.frontiersin.org/people/961943Role: Role:

John Abisheganaden: Role: Role:

Karin Dahl Assing: Role: Role:

Richard W. Costello: URI : https://loop.frontiersin.org/people/29823Role: Role:

Peter G. Gibson: Role: Role:

Enrico Heffler: URI : https://loop.frontiersin.org/people/798205Role: Role:

Jorge Máspero: Role: Role:

Stefania Nicola: Role: Role:

Diahn-Warng Perng (Steve): URI : https://loop.frontiersin.org/people/165760Role: Role:

Francesca Puggioni: URI : https://loop.frontiersin.org/people/375269Role: Role:

Sundeep Salvi: Role: Role:

Chau-Chyun Sheu: URI : https://loop.frontiersin.org/people/569036Role: Role:

Concetta Sirena: Role: Role:

Camille Taillé: URI : https://loop.frontiersin.org/people/1332123Role: Role:

Tze Lee Tan: URI : https://loop.frontiersin.org/people/2676853Role: Role:

Leif Bjermer: URI : https://loop.frontiersin.org/people/590425Role: Role:

Giorgio Walter Canonica: Role: Role:

Takashi Iwanaga: Role: Role:

Libardo Jiménez-Maldonado: URI : https://loop.frontiersin.org/people/2615258Role: Role:

Christian Taube: URI : https://loop.frontiersin.org/people/1498342Role: Role:

Luisa Brussino: URI : https://loop.frontiersin.org/people/1606862Role: Role:

David B. Price: URI : https://loop.frontiersin.org/people/647971Role: Role:

Journal

Journal ID (nlm-ta): Front Immunol

Journal ID (iso-abbrev): Front Immunol

Journal ID (publisher-id): Front. Immunol.

Title: Frontiers in Immunology

Publisher: Frontiers Media S.A.

ISSN (Electronic): 1664-3224

Publication date (Electronic): 19 April 2024

Publication date Collection: 2024

Volume: 15

Electronic Location Identifier: 1361891

Affiliations

[1] ¹ Department of Respiratory Medicine and Infectious Diseases, Research Unit, Bispebjerg Hospital , Copenhagen, Denmark

[2] ² Observational and Pragmatic Research Institute , Singapore, Singapore

[3] ³ Optimum Patient Care Global , Cambridge, United Kingdom

[4] ⁴ Department of Medicine, Centre for Lung Health, Vancouver General Hospital , Vancouver, BC, Canada

[5] ⁵ Department of Medicine, The University of British Columbia , Vancouver, BC, Canada

[6] ⁶ Faculty of Public Health, Medical University , Sofia, Bulgaria

[7] ⁷ Woolcock Institute of Medical Research, The University of Sydney , Sydney, NSW, Australia

[8] ⁸ School of Medicine, Sydney Campus, The University of Notre Dame , Sydney, NSW, Australia

[9] ⁹ Centro de Excelencia en Asma y Alergia, Hospital Médica Sur , Ciudad de México, Mexico

[10] ¹⁰ BioPharmaceuticals Medical, AstraZeneca , Gaithersburg, MD, United States

[11] ¹¹ Department of Pulmonology, King Fahad Medical City , Riyadh, Saudi Arabia

[12] ¹² College of Medicine, Alfaisal University , Riyadh, Saudi Arabia

[13] ¹³ Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University , Sydney, NSW, Australia

[14] ¹⁴ Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast , Belfast, United Kingdom

[15] ¹⁵ Allergy, Asthma and Clinical Immunology Service, Alfred Health , Melbourne, VIC, Australia

[16] ¹⁶ Public Health and Preventive Medicine, Monash University , Melbourne, VIC, Australia

[17] ¹⁷ Respiratory Medicine Department, University of Ioannina , Ioannina, Greece

[18] ¹⁸ Division of Infection, Immunity and Respiratory Medicine, University of Manchester , Manchester, United Kingdom

[19] ¹⁹ Allergy Department, 2nd Pediatric Clinic, University of Athens , Athens, Greece

[20] ²⁰ Department of Respiratory Medicine, Barts Health National Health Services (NHS) Trust , London, United Kingdom

[21] ²¹ Barts and The London School of Medicine and Dentistry, Queen Mary University of London , London, United Kingdom

[22] ²² University Hospital St. Ivan Rilski , Sofia, Bulgaria

[23] ²³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea , Seoul, Republic of Korea

[24] ²⁴ Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, The University of British Columbia , Vancouver, BC, Canada

[25] ²⁵ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung, Taiwan

[26] ²⁶ Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan

[27] ²⁷ Department of Respiratory Medicine, Copenhagen ;University Hospital - Hvidovre , Copenhagen, Denmark

[28] ²⁸ Microbiology Department, College of Medicine, Kuwait University , Kuwait City, Kuwait

[29] ²⁹ Al-Rashed Allergy Center, Ministry of Health , Kuwait City, Kuwait

[30] ³⁰ Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital , Tartu, Estonia

[31] ³¹ Son Espases University Hospital-Institut d’Investigació Sanitària Illes Balears (IdISBa)-Ciberes , Mallorca, Spain

[32] ³² Respiratory Research Unit, Bispebjerg University Hospital , Copenhagen, Denmark

[33] ³³ Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital , Copenhagen, Denmark

[34] ³⁴ Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast , Belfast, United Kingdom

[35] ³⁵ Respiratory Medicine at the School of Medicine, University of Nottingham , Nottingham, United Kingdom

[36] ³⁶ Division of Internal Medicine Asthma and Allergy, Medical University of Lodz , Lodz, Poland

[37] ³⁷ Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine , Kobe, Japan

[38] ³⁸ Department of Clinical and Experimental Sciences – University of Brescia, Spedali Civili di Brescia , Brescia, Italy

[39] ³⁹ Instituto Neumológico del Oriente , Bucaramanga, Colombia

[40] ⁴⁰ Centre Hospitalier Universitaire (CHU) Sart-Tilman, GIGA I3, University of Liege , Liège, Belgium

[41] ⁴¹ Department of Medicine, National Jewish Health (NJH) Cohen Family Asthma Institute, National Jewish Health , Denver, CO, United States

[42] ⁴² Department of Women’s and Children’s Health, Uppsala University , Uppsala, Sweden

[43] ⁴³ CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto , Porto, Portugal

[44] ⁴⁴ PhyMedExp, Univ Montpellier, National Center for Scientific Research (CNRS), The National Institute of Health and Medical Research (INSERM), Centre Hospitalier Universitaire (CHU) Montpellier , Montpellier, France

[45] ⁴⁵ Department of Respiratory Medicine, Ghent University Hospital , Ghent, Belgium

[46] ⁴⁶ Departments of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam , Rotterdam, Netherlands

[47] ⁴⁷ Saw Swee Hock School of Public Health, National University of Singapore , Singapore, Singapore

[48] ⁴⁸ Department of Respiratory Medicine, Fiona Stanley Hospital , Perth, WA, Australia

[49] ⁴⁹ Department of Medicine, Central Clinical School, Monash University , Melbourne, VIC, Australia

[50] ⁵⁰ Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health , Denver, CO, United States

[51] ⁵¹ Guy’s Severe Asthma Centre, Guy’s Hospital, King’s College London , London, United Kingdom

[52] ⁵² Department of Medicine, Lung Institute, Makerere University Lung Institute , Kampala, Uganda

[53] ⁵³ Department of Respiratory and Critical Care Medicine, Singapore General Hospital , Singapore, Singapore

[54] ⁵⁴ Medical University of Lodz , Lodz, Poland

[55] ⁵⁵ Allergy Centre, Tampere University Hospital , Tampere, Finland

[56] ⁵⁶ Faculty of Medicine and Health Technology, Tampere University , Tampere, Finland

[57] ⁵⁷ FAST and Chronic Programmes, Alexandra Hospital, National University Health System , Singapore, Singapore

[58] ⁵⁸ Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, National University Health System , Singapore, Singapore

[59] ⁵⁹ Rashid Hospital, Dubai Health Authority (DHA) , Dubai, United Arab Emirates

[60] ⁶⁰ Dubai Academic and Health Corporation , Dubai, United Arab Emirates

[61] ⁶¹ Department of Respiratory Medicine, University of Leicester , Leicester, United Kingdom

[62] ⁶² BioPharmaceutical Medical, AstraZeneca , Cambridge, United Kingdom

[63] ⁶³ Lung Division, Royal Brompton and Harefield Hospital , London, United Kingdom

[64] ⁶⁴ Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital , Singapore, Singapore

[65] ⁶⁵ 2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital , Athens, Greece

[66] ⁶⁶ Respiratory Medicine, Royal Brompton Hospital , London, United Kingdom

[67] ⁶⁷ Pneumology Service, Lucus Augusti University Hospital, Sergas (Galician Healthcare Service) Integrated Management Structure (EOXI) Lugo , Cervo, Spain

[68] ⁶⁸ Department of Thoracic Medicine, Concord Hospital , Sydney, NSW, Australia

[69] ⁶⁹ Faculty of Medicine, Health and Human Sciences, Macquarie University , Sydney, NSW, Australia

[70] ⁷⁰ Allergy and Clinical Immunology, G. Martino Hospital, University of Messina , Messina, Italy

[71] ⁷¹ Pulmonary Unit, Hospital Universitario San Ignacio , Bogotá, Colombia

[72] ⁷² School of Medicine, Pontificia Universidad Javeriana , Bogotá, Colombia

[73] ⁷³ Department of Respiratory and Critical Care Medicine, Changi General Hospital , Singapore, Singapore

[74] ⁷⁴ Centro Internacional de Investigación en Neumología (CINEUMO), Respiratory Research Center, Fundación Neumológica Colombiana , Bogotá, Colombia

[75] ⁷⁵ Universidad de La Sabana, Doctoral Biosciences , Chia, Colombia

[76] ⁷⁶ Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado School of Medicine , Aurora, CO, United States

[77] ⁷⁷ Department of Medicine and Surgery, University of Insubria , Varese, Italy

[78] ⁷⁸ Health Services and Outcomes Research, National Healthcare Group , Singapore, Singapore

[79] ⁷⁹ Lee Kong Chian School of Medicine, Nanyang Technological University , Singapore, Singapore

[80] ⁸⁰ Department of Respiratory Medicine, Aalborg University Hospital , Aalborg, Denmark

[81] ⁸¹ Department of Respiratory Medicine, Clinical Research Centre, Smurfit Building Beaumont Hospital, Royal College of Surgeons Ireland (RCSI) , Dublin, Ireland

[82] ⁸² Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle , Newcastle, NSW, Australia

[83] ⁸³ Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital , Newcastle, NSW, Australia

[84] ⁸⁴ Personalized Medicine, Asthma and Allergy, Istituto Clinico Humanitas, Humanitas Cancer Center (IRCCS) Humanitas Research Hospital , Rozzano, Italy

[85] ⁸⁵ Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Italy

[86] ⁸⁶ Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation , Buenos Aires, Argentina

[87] ⁸⁷ University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine , Buenos Aires, Argentina

[88] ⁸⁸ Allergy and Immunology Unit, L'Azienda Ospedaliera (AO) Ordine Mauriziano di Torino , Turin, Italy

[89] ⁸⁹ School of Medicine, National Yang Ming Chiao Tung University , Taipei, Taiwan

[90] ⁹⁰ Department of Chest Medicine, Taipei Veterans General Hospital , Taipei, Taiwan

[91] ⁹¹ Pulmocare Research and Education Foundation , Pune, India

[92] ⁹² Severe Asthma Network Italy (SANI) , Milano, Italy

[93] ⁹³ Department of Respiratory Diseases, Bichat Hospital, l'Assistance publique – Hôpitaux de Paris (AP-HP) Nord-Université Paris Cité , Paris, France

[94] ⁹⁴ Department of Family Medicine, National University Health System , Singapore, Singapore

[95] ⁹⁵ Respiratory Medicine and Allergology, Department of Clinical Sciences, Skåne University Hospital, Lund University , Lund, Sweden

[96] ⁹⁶ Kindai University Hospital , Osakasayama, Japan

[97] ⁹⁷ Fundación Neumológica Colombiana, ASMAIRE REXPIRA (Atención integral y rehabilitación en asma or Comprehensive Care and Rehabilitation in Asthma) Program , Bogotá, Colombia

[98] ⁹⁸ Department of Pulmonary Medicine, University Medical Center Essen-Ruhrlandklinik , Essen, Germany

[99] ⁹⁹ Department of Medical Sciences, University of Turin , Turin, Italy

[100] ¹⁰⁰ Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen , Aberdeen, United Kingdom

Author notes

Edited by: Harissios Vliagoftis, University of Alberta, Canada

Reviewed by: Adil Adatia, University of Alberta, Canada

Santi Nolasco, University of Catania, Italy

*Correspondence: David B. Price, dprice@ 123456opri.sg

Article

DOI: 10.3389/fimmu.2024.1361891

PMC ID: 11070939

PubMed ID: 38711495

SO-VID: 129b13f1-f188-4bea-b3c0-6a619a916449

Copyright © Copyright © 2024 Porsbjerg, Townend, Bergeron, Christoff, Katsoulotos, Larenas-Linnemann, Tran, Al-Lehebi, Bosnic-Anticevich, Busby, Hew, Kostikas, Papadopoulos, Pfeffer, Popov, Rhee, Sadatsafavi, Tsai, Ulrik, Al-Ahmad, Altraja, Beastall, Bulathsinhala, Carter, Cosio, Fletton, Hansen, Heaney, Hubbard, Kuna, Murray, Nagano, Pini, Cano Rosales, Schleich, Wechsler, Amaral, Bourdin, Brusselle, Chen, Chung, Denton, Fonseca, Hoyte, Jackson, Katial, Kirenga, Koh, Ławkiedraj, Lehtimäki, Liew, Mahboub, Martin, Menzies-Gow, Pang, Papaioannou, Patel, Perez-De-Llano, Peters, Ricciardi, Rodríguez-Cáceres, Solarte, Tay, Torres-Duque, Wang, Zappa, Abisheganaden, Assing, Costello, Gibson, Heffler, Máspero, Nicola, Perng (Steve), Puggioni, Salvi, Sheu, Sirena, Taillé, Tan, Bjermer, Canonica, Iwanaga, Jiménez-Maldonado, Taube, Brussino and Price

License:

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

History

Date received : 27 December 2023

Date accepted : 29 March 2024

Page count

Figures: 5, Tables: 3, Equations: 0, References: 58, Pages: 21, Words: 9265

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global (OPCG) and AstraZeneca Ltd. No funding was received by the OPRI for its contribution. The International Severe Asthma Registry (ISAR) is operated by OPCG and co-funded by OPCG and AstraZeneca.

Custom metadata

section-in-acceptance Inflammation

ScienceOpen disciplines: Immunology

Keywords: severe asthma,biomarkers,eosinophil (eos),feno (fraction of exhaled nitric oxide),biologics,fev1,personalized medicine (pm)

Data availability: